Jean‐Claude Chomel

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul et al. · Journal of Clinical Oncology · 2013 · 409 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Modification of enzymatic-ally amplified DNA for the detection of point mutations

A. Haliassos, Jean‐Claude Chomel, Laurent Tesson et al. · Nucleic Acids Research · 1989 · 322 citations

Life Sciences, Genetics, Molecular Genetics +13

Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France

Mireille Claustres, Caroline Guittard, Dominique Bozon et al. · Human Mutation · 2000 · 250 citations

Life Sciences, Genetics, Molecular Genetics +11

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

Jean‐Claude Chomel, Marie‐Laure Bonnet, Nathalie Sorel et al. · Blood · 2011 · 196 citations · Full text

Medicine, Hematology, Oncology +16

Detection of minority point mutations by modified PCR technique: a new approach for a sensitive diagnosis of tumor-progression markers

A. Haliassos, Jean‐Claude Chomel, S Grandjouan et al. · Nucleic Acids Research · 1989 · 178 citations · Full text

Medicine, Genetics, Molecular Genetics +17